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Background & aims: Refractory celiac disease type II (RCDII) and EATL (Enteropathy Associated T-cell
Lymphoma) are (pre)malignant complications of celiac disease (CD). Data on malnutrition and intestinal
absorption is lacking in these patients. Therefore, the aim of the study is to comprehensively assess
nutritional status and intestinal absorption capacity of patients with RCDII and EATL, compared with data
of newly diagnosed CD patients.
Methods: Observational study in tertiary care setting in RCDII (n ¼ 24, 63.8 ± 8.2 y), EATL (n ¼ 25,
62.3 ± 5.7 y) and CD patients (n ¼ 43, 45.6 ± 14.8 y). At diagnosis, anthropometry (BMI, unintentional
weight loss, fat-free mass index (FFMI), handgrip strength (HGS), nutritional intake, fecal losses and
Resting Energy Expenditure (REE)) were assessed.
Results: Low BMI (<18.5) was more often observed in RCDII patients than in CD or EATL patients (in 33%,
12% and 12%, respectively, p ¼ 0.029). EATL patients more frequently had unintentional weight loss
(>10%) than CD or RCDII patients (in 58%, 19% and 39% of patients, respectively; p ¼ 0.005/0.082). Energy
malabsorption (<85%) was detected in 44% and 33% of RCDII and EATL patients, vs 21.6% in CD (NS). Fecal
energy losses were higher in RCDII than in CD patients (589 ± 451 vs 277 ± 137 kcal/d, p ¼ 0.017). REE
was underestimated by predicted-REE with>10% in 60% of RCDII, 89% of EATL, and 38% of CD patients
(p ¼ 0.006). Low FFMI and HGS were detected in one third and two thirds of all patients, respectively.
Conclusions: The nutritional status of patients with RCDII and EATL is inferior compared with untreated
naïve CD patients at presentation. Both malabsorption as well as hypermetabolism contribute to
malnutrition.
© 2015 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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d/4.0/).1. Introduction
Celiac disease (CD) is deﬁned as an immune-mediated chronic
enteropathy, caused by an irreversible intolerance for gluten in
individuals who are genetically susceptible. Its prevalence has been
estimated to be 0.5%e1% [1]. Histopathological characteristics
comprise a variable degree of villous atrophy, crypt hyperplasia and
intra-epithelial lymphocytosis, primarily in duodenum and
jejunum [2,3]. The only accepted treatment is a strict and lifelong
adherence to a gluten free diet (GFD), which interrupts the immune
response triggered by gluten.
Most patients improve clinically within several weeks to
months after instigation of a GFD [4]. In a substantial number of
patients mucosal recovery is delayed and may last until 2 years
after initiation of a strict diet [5e8]. A small minority of patientscal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
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improve clinically upon a strict GFD for over 12 months (primary
resistance) or shows a relapse (secondary resistance). The most
common cause for refractoriness to a GFD is unintentional
contamination with gluten [8] or an (associated) disorder of the
small bowel resembling CD. When dietary adherence is meticu-
lously evaluated by a skilled dietician and other reasons for villous
atrophy have been ruled out, patients are diagnosed with refractory
CD (RCD). RCD is subdivided into 2 types based on the non-
presence (type I) or presence (type II) of abnormal intraepithelial
lymphocytes (IELs) referred to as aberrant lymphocytes [9], the cut-
off for RCDII being >20% [10]. These 2 groups differ fundamentally
since RCDII, in contrast to RCDI, may be considered as a low-grade
lymphoma that may develop into a (destructive) enteropathy-
associated-T-cell lymphoma (EATL) with an excessive mortality
[11]. Untreated, 60e80% of RCDII patients develop an EATL within 5
years. However, EATL may also develop in association with un-
complicated (secondary EATL) or unknown CD (primary EATL).
Symptoms in uncomplicated active CD patients may include
diarrhea, abdominal pain, fatigue, malaise, deﬁciencies and weight
loss, although clinical signs may also be succinct or even absent.
Based on clinical presentation, RCDII and EATL patients show
overlapping characteristics with ‘active’ or untreated CD; ongoing
weight loss, diarrhea and fatty stools are usual and refractory to
dietetic treatment, thus, adherence to a strict GFD [12,13]. Unsuit-
ably, literature regarding other nutritional parameters and energy
expenditure in both RCDII and EATL is lacking.
Since the pathophysiology and etiology of malnutrition are
complex, it appears inappropriate to assess nutritional status and
its possible determinants (e.g. malabsorption and increased meta-
bolism) on the basis of a single parameter, ignoring/neglecting
temporal weight loss, Body Mass Index (BMI), body composition,
functional indices, intestinal absorption and basal metabolism.
Therefore, the aim of this study was to perform a comprehensive
assessment of the nutritional status and energy balance of patients
with RCDII and EATL and to compare these results with newly
diagnosed, naive CD patients.2. Materials and methods
This observational cross sectional study was performed in
recently diagnosed, naive CD, RCDII and EATL patients. Nutritional
status was determined according to three independent variables: 1)
current BMI and percentage of weight loss (unintentionally) during
the 6 months prior to diagnosis; 2) body composition and 3) a
parameter of functionality being handgrip strength (HGS). Energy
balance was determined evaluating nutritional intake, fecal losses
and Resting Energy Expenditure (REE). Energy balance (kcal/d) was
calculated as the difference between energy intake and ‘total en-
ergy use’, the latter being calculated as Total Energy Expenditure
(TEE) plus fecal energy loss. All measurements were performed in
one routinely medical appointment by an experienced dietician.2.1. Patients
During the period 2005e2013, all consecutively diagnosed adult
RCDII or EATL patients from the outpatient clinic of the VU Uni-
versity Medical Centre, Amsterdam, the Netherlands, were
enrolled. Besides, newly diagnosed (naïve) CD patients were
concurrently and consecutively recruited. Patients either consumed
a normal or standard Dutch western and gluten containing diet
(newly diagnosed CD and primary EATL patients) or a GFD for at
least 12 months prior to diagnosis (RCDII patients and EATL pa-
tients secondary to a former diagnosis of CD or RCDII).2.2. Diagnosis of CD, RCDII and EATL
Anti-endomysial (EMA) and anti-transglutaminase antibodies
(tTG), i.e. the CD associated antibodies, were determined. In addi-
tion, HLA-genotyping was determined, to analyze the incidence of
DQ2 and DQ8 haplotypes as a requirement for a conclusive diag-
nosis. Duodenal biopsy specimens were gathered to deﬁne the
grade of histological impairment as classiﬁed by Marsh [14]
(modiﬁed by Rostami [15,16]), the gold standard method of diag-
nosis of CD.
CD diagnosis relied on the demonstration of partial or complete
villous atrophy (Marsh IIIA-C), and the detection of CD-related
antibodies and the presence of CD-related genotypes. In the CD
patient group, patients with low grade histopathological abnor-
malities (Marsh I or II, i.e. lymphocytic enteritis with crypt hyper-
plasia) could only and exceptionally be included in case of family
screening, together with presence of gluten-dependent disorders,
in combination with elevated CD associated antibodies and HLA-
DQ2 or HLA-DQ8 haplotype.
The RCDII diagnosis was based on recurring or persisting clinical
symptoms and villous atrophy of the small intestine (Marsh IIIA-C)
which remained or reoccurred in spite of a strict GFD for over a year
and at the exclusion of other villous atrophy causes. Furthermore,
the clinically endorsed cut-off value of over 20% aberrant IELs
(perceived by ﬂow cytometric analysis) was used to diagnose RCDII
[10]. The EATL diagnosis was based on the criteria according to the
WHO Classiﬁcation of Tumors of Hematopoietic and Lymphoid
Tissues. Diagnosis was conﬁrmed histologically by our expert
pathologist. Primary EATL was deﬁned as diagnosis of EATL in pa-
tients without a preceding CD history or when diagnosis of both
EATL and CD were made at the same time or with a maximal six-
months-interval. Inconclusive or negative serology was not an
exclusion criteria in all patients groups, when patients met the
villous atrophy and CD-related genotype criteria.
The study protocol was approved by the Medical Ethics Com-
mittee of the VU University Medical Centre Amsterdam, The
Netherlands. All patients provided informed consent.
2.3. Nutritional status
2.3.1. BMI and weight loss
Patient characteristics, demographic data and anthropometric
data were collected directly after diagnosis and before dietary
treatment to either initiate a GFD (CD patients) or nutritional
support (RCD or EATL patients). Nutritional status parameters
included body weight (in kg, measured on a digital electronic scale
(with an accuracy of 0.1 kg), and self-reported body height (m) and
weight loss (involuntary in kg) in the past one month and in the
past six months. Patients were classiﬁed into three BMI cohorts
(based on the World Health Organization's deﬁnition (2000)): BMI
up to 18.5 kg/m2 (underweight), 18.5e25.0 kg/m2 (normal weight)
and over 25 kg/m2 (overweight, or ‘obese’ when BMI exceeded
30 kg/m2). Patients were classiﬁed as ‘malnourished’ in case of
unintentional loss of body weight of more than 10% in the past six
months or more than 5% loss of body weight in the month previous
to diagnosis. Patients were classiﬁed as having ‘risk of malnutrition’
in case of 5%e10% loss of bodyw eight (unintentionally) in the six
months prior to diagnosis. Overall patients were classiﬁed as hav-
ing a ‘normal nutritional status’ when BMI exceeded 18.5 and no
weight loss (<10% in past six months or <5% in one month)
occurred.
2.3.2. Body composition
Body composition was measured using (the 50 KHz data of) a
multiple frequency bioelectrical impedance analyzer (Hydra ECF/
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nologies, San Diego, CA, USA). During the test, patients were placed
in a supine position without socks and shoes. Four adhesive elec-
trodes (3 M Red Tod T, 3 M Health care, Borken, Germany) were
attached to the skin in a standard tetrapolar position; at the dorsal
sides of the dominant hand and foot and at the distal metacarpals
and metatarsals. Whole-body reactance and resistance were
measured by an electronic current (50 kHz). The fat freemass (in kg
and %, FFM) was calculated by the equation of Kyle [17]. The fat free
mass index (in kg/m2, FFMI) was calculated as FFM (kg)/height2 (in
m). Cut-off values for FFMI were <16.7 FFM kg/m2 for men, and
<14.6 FFM kg/m2 for women, respectively [17].
2.3.3. Handgrip strength
Handgrip strength of the non-dominant arm was measured
using a Physio-Med Baseline Hydraulic handgrip dynamometer.
During the test, patients were asked to sit in a relaxed position,
facing the back of the dynamometer display. The arm which was
tested was not supported during the test and the elbow was in 90
ﬂexion. The highest of three recorded measurements was taken
into account in subsequent analysis. Age, gender, and sex speciﬁc
reference values for handgrip strength were used, according to
Bohannon [18]. Values below the 10th percentile were considered
as decreased (or too low).
2.4. Energy balance
2.4.1. Nutritional intake
During four consecutive days, patients were asked to report
their nutritional (solid and liquids) intake in a nutritional diary. A
skilled and experienced dietician instructed all patients beforehand
regarding accurate weighing of all foods and beverages. The use of
digital electronic scale was advised and speciﬁc dietary information
was recorded, including cooking methods and brand names, if any,
for all foods and beverages consumed during the study period.
Besides, the dietitian interviewed all patients afterwards to com-
plete the records and to check whether all study procedures had
meticulously been followed. A computerized food calculation pro-
gram based on the National Dutch Food Composition Table ‘NEVO’
2006 [19], was applied to calculate nutrient intake (fat, protein and
carbohydrates). The total dietary energy intake (TEI) was calculated
using gross energetic values for the macronutrients [20], as
described extensively elsewhere [3].
2.4.2. Fecal loss
All stools were collected during a period of exactly 72 h (day 2e4
of study), as per protocol, in 5 L fecal collection buckets. The pa-
tients were instructed to keep the feces stored in a dry and cool
place during the collection period. Feces was weighed (‘wet’) upon
arrival in the lab(in g/d, FWW), homogenized and instantly stored
at <4 C till analysis. Feceswas analyzed for energy, fat and nitrogen
content, in order to calculate intestinal absorption capacity for
these macronutrients. The fat content of the feces (FFat) was
measured by the Van de Kamer method [21]. The nitrogen content
of the feces (FNitrogen), was analyzed by the micro-Kjeldahl method,
developed for wet stool samples, using formerly described diges-
tive and catalytic conditions [22]. Fecal protein content (FProtein)
was calculated using a ﬁxed conversion factor, supposing that all of
the fecal nitrogen content was a resultant of protein. In formula:
FProtein (g/d) ¼ FNitrogen (g/d) 6.25. The caloric value of FProtein was
calculated as FProtein 4.4 kcal/d. Next, a fecal sample was reserved,
freeze dried and prepared to process by bomb calorimetry (as
described elsewhere) [3,23,24]. The fecal calorimetric determina-
tion represented the total daily energy loss by feces (FEnergy) in kcal/
d. They were performed at the laboratory of University MedicalCenter Groningen, The Netherlands, with a Gallenkamp Ballistic
bomb calorimeter (type CBB-33). Finally, the fecal ‘rest’ energy, i.e.
the fecal energy content which does not reﬂect the caloric value of
fecal-fat or fecal-protein, was deﬁned as the fecal carbohydrate
(FCarbohydrate) content in this study. . In formula: FCarbohydrate (g/
d) ¼ (FEnergy  FFat 9.4  FProtein 4.4)/4.10. Subsequently, the
intestinal absorption capacity of ingested energy from macronu-
trients (in %), was calculated as: (TEI  FEnergy/TEI) 100%. Malab-
sorption of energy or macronutrients (fat, protein and
carbohydrate) was a priori determined as a cut-off value of <85%
and severe malabsorption as <75% intestinal absorption [25,26].
2.4.3. Energy expenditure
Resting Energy Expenditure (REE) was assessed by indirect
calorimetry (using Datex Deltatrac, Helsinki, Finland). The equip-
ment was calibrated before eachmeasurement, with calibration gas
(95% oxygen and 5% carbon dioxide, Quick cal, GE Health care,
Helsinki, Finland). Patients were instructed to lie in supine position
and at complete rest when measurements were performed,
throughout the total time of 30 min as a minimum. Steady state
periods of measurements were selected, i.e. periods where carbon
dioxide production and oxygen consumption were measured with
a coefﬁcient of variation beneath 10%. The Weir Equation was used
by de Datex Deltatrec to calculate REE. Measured REE was
compared to predicted REE according to the commonly used sex
and age speciﬁc equation of Harris and Benedict [27]. Measure-
ments were classiﬁed as ‘well estimated’ byHB-prediction equation
when measured REE ﬁtted between 90 and 110% of predicted REE,
as ‘overestimated’ when REE was less than 90% of predicted REE
and ‘underestimated’ by HB-prediction equation when measured
REE was more than 110% of predicted REE. The latter was, in this
study, deﬁned as ‘hypermetabolism’. Moreover, REE was also pre-
sented corrected for body weight (in kcal/kg) and FFM (in kcal/kg
FFM) despite different nutritional status between patient groups.
Patients' Total Energy Expenditure (TEE) was calculated as
measured REE þ 30% for physical activity.
2.5. Statistical considerations
All data of the included patients are presented as means ± SD.
Groups were compared with Students' t-test or analysis of variance
(ANOVA) for continuous variables plus a Bonferroni correction once
statistical signiﬁcance was attained. ManneWhitney U test/Wil-
coxon or KruskaleWallis test, in case of more than two groups,
were applied for continuous variables without a normal distribu-
tion. Pearson's correlation coefﬁcient (r) and Chi Square test (for
dichotomous variables and percentages) were used to study asso-
ciations between variables, where appropriate. The level of statis-
tical signiﬁcance was set at p < 0.05. The statistical analyses were
performed by use of the software package SPSS (Statistical Package
for Social Sciences Inc., Chicago, IL, USA for Windows version 20).
3. Results
3.1. Patients
Ninety-two patients were included. Baseline characteristics of
the total group and the three subgroups (CD n ¼ 43, RCDII n ¼ 24,
EATL n ¼ 25) are presented in Table 1. Of the 25 included EATL
patients, 15 (60%) suffered from primary EATL, 4 patients (16%)
presented with a secondary EATL following uncomplicated CD and
6 (24%) suffered from secondary EATL following RCDII. RCDII and
EATL patients were statistical signiﬁcantly older than CD patients at
diagnosis.
Table 1
Patients characteristics (mean ± SD or N) of patients with RCDII and EATL versus CD at presentation.
CD (43) RCDII (24) EATL (25) p-value (ANOVA)
Sex (N) 28 F/15 M 11 F/13 M 12 F/13 M 0.219
Age (year) (range) 45.6 ± 14.8 (21e75) 63.8 ± 8.2 (45e78) 62.3 ± 5.7 (51e71) <0.001a
Height (m) 1.71 ± 0.11 1.70 ± 0.1 1.72 ± 0.1 0.8471
Weight (kg) 69.2 ± 16.3 60.9 ± 10.6 64.0 ± 9.9 0.044b
Marsh classiﬁcation (N) I/IIc 6 1 2
IIIA 22 1 9
IIIB 8 9 8
IIIC 7 4 6
Antibodies EMA/tTG(N) Negative 11 18 11
Inconclusive 4 3 0
Positive 27 1 14
n.d. 1 2 0
% Aberrant cells n.d. 60.1 ± 23.6 26.1 ± 31.6 <0.001d
CD genotypes (N) DQ2 (heterozygote) 27 13 9 0.03e
DQ2 (homozygote) 3 9 13
DQ8 (heterozygote) 3 0 0
DQ2 and DQ8 2 1 2
DQ2 nor DQ8 2 1 0
n.d. 6 0 1
p<0.05
a CD younger than RCDII and EATL.
b RCDII lower weight than CD.
c Low grade histopathological abnormality plus HLA-DQ2 and/or DQ8 plus elevated CD associated antibodies (EMA and/or tTG).
d n.d. not determined, Student's t-tests.
e Pearson Chi-square test.
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Data on nutritional status are presented in Table 2. Underweight
(BMI <18.5 kg/m2) was present in 16 patients, more often in RCDII
patients than in naive CD or EATL patients (33.3 vs 12 and 12%,
p ¼ 0.029). Moreover, mean BMI was lower in RCDII than in naïve
CD patients (20.9 ± 2.6 and 23.4 ± 4.3 kg/m2, p¼ 0.012). Thirty-one
patients of the total group were classiﬁed as malnourished having
suffered >10% weight loss (unintentionally) in the past 6 months.
EATL patients expressed, on average, the highest percentage un-
intentional weight loss (p ¼ 0.005). Moreover a higher proportion
of patients in this group suffered from malnutrition (>10% unin-
tentional weight loss) compared to naive CD or RCDII patients (58.3,
39.1 and 19.0%, respectively; p ¼ 0.001). Figure 1 depicts an over-
view of nutritional status with regard to weight loss (uninten-
tionally, >10% in past 6 months) and low BMI (<18.5 kg/m2) in theTable 2
Nutritional status (mean ± SD) of patients with RCDII and EATL versus uncomplicated C
CD novo (43) RCDII




%Weight loss (N) 3.2 ± 6.1 (42) 6.5 ±
%Malnourishedd 19.0 39.1
FFMd (kg) (N) 47.4 ± 11.6 (34) 47.9 ±
FFM (%) 71.0 ± 7.9 78.2 ±
FMd (kg) 19.5 ± 7.6 14.9 ±
FM (%) 29.0 ± 7.9 24.0 ±
FFMId (kg/m2) 16.4 ± 2.8 16.3 ±
% poor 29.4 35.3
HGSd kg (N) 30.3 ± 11.9 (38) 27.8 ±
<P10d (%) 47.4 66.7
p<0.05
a RCDII lower BMI than CD.
b EATL more % unintentional weight loss than CD (p ¼ 0.04) and trend with RCDII (p
c RCDII trend for higher % FFM and lower kg FM than CD.
d Malnourished classiﬁed as >10% weight loss (unintentional) in the past 6 months, FM
Bohannon's reference.
e ANOVA.
f Chi-square.three patient groups. FFMI and HGS data did not different between
the three groups and, additionally, these were below cut-off values
in one-third and two-third of all patients, successively. FFMI and
BMI were positively correlated (Pearsons r 0.593, p < 0.001). But
19% of the patients with a normal/high BMI still had a decreased
FFMI and 25% a decreased HGS. Of the 49 patients classiﬁed with a
normal nutritional status (i.e. no WL and a normal BMI), 21% still
had a low FFMI and 17% a low HGS.3.3. Energy balance
Data on nutritional intake, fecal losses, intestinal absorption
capacity, measured REE and calculated energy balance are depicted
in Table 3. No statistical differences were detected between the
three groups in energy nor macronutrient intake.D at presentation.
(24) EATL (25) p-value




8.7 (23) 17.5 ± 30.4 (24) 0.005b, e
58.3 0.001d
10.5 (17) 48.8 ± 10.0 (15) 0.915e
14.1 75.6 ± 9.3 0.052c, e
7.1 15.7 ± 6.2 0.058c, e
9.6 24.4 ± 9.4 0.09e
2.6 16.6 ± 1.8 0.964e
20.0 0.503f
9.6 (18) 27.1 ± 9.8 (16) 0.538e
62.5 0.326f
¼ 0.082).
: fat mass, FFM(I): fat free mass (index), HGS: handgrip strength, <P10 according to
Fig. 1. Distribution of nutritional status based on combined (unintentional) weight loss
and BMI in CD, RCDII and EATL patients.
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Absolute values of 30 min measured REE, did not seem to differ
between the three groups, however there were statistical differ-
ences in the percentage of patients with predicted underestimation
(p ¼ 0.006) Measured REE was over 10% higher than the predicted
REE in 89% of the EATL patients, with a mean difference of 311 kcal/
day, whereas the measured REE was over 10% higher than the
predicted REE in 60% of the RCDII patients, representing a mean
underestimation of 305 kcal/d. In naive CD patients, REE was
underestimated in 38% of patients. REE adjusted for body weight
(REE/kg) and FFM (REE/kg FFM) did not differ between the three
patients groups, although there was a trend for higher REE/kg body
weight in both RCDII and EATL patients (p ¼ 0.06). EATL patients
had a higher adjusted REE for body weight (t-test, p ¼ 0.036) and a
trend for higher FFM adjusted REE (t-test, p ¼ 0.082), compared to
CD patients. Similarly, a statistical trend was seen for the RCDII
versus CD patients (t-test, p ¼ 0.069) on body weight adjusted REE
(kcal/kg).Table 3
Nutritional intake, Resting Energy Expenditure, fecal losses and intestinal absorption capa
CD novo (43) R
Nutritional intake
Energy (kcal/d) 2457 ± 660 2
Fat (g/d) 88.7 ± 28.3 1
Protein (g/d) 86.0 ± 26.2 9
Carbohydrate (g/d) 291.6 ± 89.9 3
Resting Energy Expenditured
REE measured (kcal/d) (N) 1596 ± 296 (42) 1
REE predicted (kcal/d) 1512 ± 238 1
Measured REEepredicted REE (kcal/d) 196 ± 30 (328 e þ673) 3
% Underestimated REE (>10%) 38.1% 6
REE/kg (kcal/kg) 23.8 ± 4.6 2
REE/kg FFM* (kcal/kg) 33.3 ± 5.9 3
Fecal losses and intestinal absorption capacity
Fecal production (g/d) (N) 242 ± 183 (39) 6
Fecalenergy(kcal/d) 277 ± 137 5
Energy absorption (%) 88.6 ± 5.0 7
% Malabsorption (<85%) 21.6% 4
Fecalfat (g/d) 8.5 ± 5.4 2
Fat absorption (%) 90.2 ± 6.7 7
%Malabsorption (<85%) 21.6% 4
Fecalnitrogen (g/d) 2.0 ± 0.9 3
Protein absorption (%) 84.8 ± 7.0 7
%Malabsorption (<85%) 48.6% 4
Fecalcarbohydrate (g/d) 35.2 ± 21.4 6
Carbohydrate absorption (%) 87.1 ± 6.9 7
%Malabsorption (<85%) 37.8% 4
Energy balance
%Negative (>100 kcal/d) 25.6% 2
*p<0.05
a EATL higher deviation from predicted REE formula than CD.
b RCDII higher fecal energy loss/lower energy absorption than CD.
c RCDII higher fecal fat loss and lower fat absorption than CD.
d REE: Resting Energy Expenditure, measured with indirect calorimetry or predicted w
e ANOVA.
f Chi-square.3.3.2. Intestinal absorption capacity
Fecal energy, fat loss and subsequent malabsorption of macro-
nutrients were most aberrant, and therefore disadvantageous, in
RCDII patients. A trend was seen for protein and carbohydrate ab-
sorption (fecal loss and malabsorption) when comparing RCDII and
EATL with naive CD patients, whereas no differences could be
detected between RCDII and EATL patients. Severe malabsorption
(<75%) was more often present in complicated CD, that is in
17.6e38.9% (depending on energy or macronutrients) of the RCDII
patients, 6.7e20% of the EATL patients, but only in 2.7e8.1% of the
naive CD patients. When comparing patient cohorts with no
malabsorption, malabsorption or severe malabsorption, a statisti-
cally signiﬁcant difference was observed for fat absorption
(p ¼ 0.025) and a trend for energy absorption (p ¼ 0.056). This
indicated that naive CD patients more frequently had a normal fat
and energy absorption if compared to RCDII and EATL patients. The
combination of energy intake, TEE and fecal energy loss resulted in
a negative energy balance of >100 kcal/d in 20e28% of all patients
(no differences between groups).
4. Discussion
It is generally accepted that malnutrition and diarrhea may be
serious problems in active or naive CD and, more extensively, in its
complicated forms, RCDII and EATL. This negatively inﬂuences
general health, wellbeing, quality of life, morbidity and mortality
[28]. The present study describes and compares the nutritional
status of naive CD, RCDII and EATL patients in a comprehensiveway,
focusing on anthropometrics, body composition, energy expendi-
ture and muscle strength. In the particular group of RCDII and EATL
patients, nutritional status was seriously affected at presentation,
even when compared to newly diagnosed, naive CD-patients, ascity (mean ± SD, (range)) of patients with RCDII and EATL versus CD at presentation.
CDII (24) EATL (25) p-value
882 ± 708 2736 ± 1357 0.205e
08.5 ± 38.3 95.5 ± 58.4 0.203e
9.7 ± 26.6 95.1 ± 49.5 0.311e
37.3 ± 83.4 338.2 ± 172.6 0.229e
595 ± 365 (20) 1724 ± 344 (18) 0.340e
368 ± 200 1413 ± 194 0.042e
05 ± 68 (208 e þ775) 311 ± 303 (220 e þ953) 0.005a, e
0.0% 8.9% 0.006f
6.2 ± 5.5 26.8 ± 5.5 0.060e
3.8 ± 5.3 37.0 ± 8.1 0.174e
18 ± 913 (18) 852 ± 2365 (16) 0.196e
89 ± 451 506 ± 680 0.017b, e
6.9 ± 23.0 83.4 ± 13.2 0.014b, e
4.4% 33.3% 0.212f
1.7 ± 20.6 15.8 ± 16.9 0.003c, e
7.5 ± 23.2 83.0 ± 11.6 0.006c, e
7.1% 46.7% 0.085f
.2 ± 2.1 3.3 ± 4.0 0.070e
6.4 ± 23.0 73.9 ± 25.1 0.065e
6.7% 53.3% 0.930f
9.4 ± 60.5 65.2 ± 103.3 0.078e
7.6 ± 23.9 84.3 ± 15.4 0.096e
6.7% 33.3% 0.743f
0.8% 28% 0.850f
ith Harris and Benedict equation, FFM: fat free mass.
N.J. Wierdsma et al. / Clinical Nutrition 35 (2016) 685e691690reﬂected by the high number of patients with involuntary weight
loss and loss of muscle mass or muscle strength. This observation
may be attributed to a combination of a (unexpectedly) high REE
and decreased intestinal absorption. Nutritional status and energy
balance are known to be affected in CD patients at diagnosis; in
patients with RCDII or EATL, nutritional status may even be
described as endangered.
The nutritional status of uncomplicated, naive CD patients, in
contrast to that of RCDII or EATL patients, has been studied before,
especially with regard to BMI and body composition. Lower body
weights, BMI, FM and FFM have been reported [29]. Untreated CD
patients have a BMI that is approximately 2.3 points lower than that
in controls, but this is usually reversible on a GFD. In this study, 30%
of the currently diagnosed, naive celiacs even had overweight at
presentation, in contrast to 16% of the EATL patients, while over-
weight was practically not present in RCDII patients (4%). Reported
mean BMI in untreated, uncomplicated CD patients is 19.0e24.0 kg/
m2, which is comparable with the observed data in the current CD
population [30e32].
Body composition (FM and FFM) of CD patients was studies
before, showing a decreased FM in both treated and untreated CD
patients if compared to healthy controls [30,31,33e36]. In this
study, the more reliable method FFMI (FFM adjusted for height)
was presented and appeared to be impaired in approximately one-
third of the naïve CD, RCDII and EATL patients. As expected FFMI
and BMI correlated reasonably well; indicating that a higher BMI
correlated with a higher FFMI (or vice versa). Besides, it is known
that nutritional status has a great impact on muscle strength, a
ﬁnding which has been corroborated by our hand-grip strength
data. Approximately two out of three RCDII or EATL patients had
low handgrip strengths, consistent with a negatively affected
nutritional status in all studied groups. More remarkably data of
this study were that one-ﬁfth of the patients with a normal/high
BMI still had a decreased FFMI and a quarter had a decreased HGS.
Of the patients classiﬁed with a normal nutritional status, this was
21% and 17%, respectively.
In two prior studies, REE was examined in CD patients [35,36].
REE was found to be higher in patients with CD than in controls,
also after adjustment for sex, age and body composition. In the
present study, no statistical differences in (uncorrected) measured
REE between naive CD, RCDII and EATL patients were observed.
However, when comparing measured (objectiﬁed) REE to predicted
(calculated) REE, the frequently used prediction equation of Harris
and Benedict underestimated the measured REE in 60% and 89% of
EATL and RCDII patients, respectively. In uncomplicated naive CD
patients, 39% was incorrectly predicted (calculated). The applied
prediction equation (H&B) therefore seems not to be suitable for
these (complicated) CD-patients. An energy expenditure higher
than expected appeared to contribute to this incorrect prediction of
calculated REE. This may be interpreted as hypermetabolism, which
seems a feature of serious disease in EATL patients, and possibly
also in RCDII patients.
Remarkably, although malabsorption is frequently linked to (R)
CD or EATL in literature, it has not been quantiﬁed before. In this
study it was present in 20e50% of the various CD patient groups.
Fecal energy losses were considerably higher (two-fold) in RCDII
and EATL patients than in naive CD patients, i.e. nearly 600 kcal/
d versus 277 kcal/d, and subsequent malabsorption (<85%) was
prevalent in 44% vs 21% of the two patient groups. Energy loss was
accompanied by loss of all macronutrients; overall, and not unex-
pectedly, energy and macronutrient losses were higher in compli-
cated CD patients, contributing to the clinical characteristics of
these illnesses. Patients with complicated CD had a higher fecal
production than CD patients, although not statistically signiﬁcant,
due to a large spread and range in relatively small patient groups. Inan earlier study we already demonstrated that intestinal function
was reduced in patients with CD and RCD, since generation of
citrulline out of glutamine was impaired, indicative for a gradual
enterocyte mass decline in these patients groups [37].
Previous data on nutritional status in RCDII and EATL patients,
including body composition, handgrip strength and energy
expenditure, are not available. It has been described that weight
loss is common in RCDII patients, also in patients receiving treat-
ment, but a comprehensive assessment of nutritional status has not
been described before. One observational study was conducted in a
small group of nine RCD patients, showing that weight loss was one
of the most common presenting symptoms [38]. This is in accor-
dance with the present study in which involuntary weight loss
>10% was existing in 40% of the RCDII patients at presentation.
Actually, and in EATL patients in particular, sizeable involuntary
weight loss (malnutrition) was one of the most characteristic fea-
tures (60% of the patients at presentation). On the contrary, RCDII
patients were more often characterized by a more chronic form of
malnutrition, i.e. a low BMI.
In addition, 52% of EATL patients were homozygote for DQ2,
compared to 37% of the RCDII patients and only 7% of the CD pa-
tients. Homozygosis for HLA-DQ2 has been demonstrated to be
related to RCDII and EATL before. Identiﬁcation of HLA-DQ2 ho-
mozygous CD patients at an early stage, may be helpful to identify
the CD patients susceptible for developing these severe complica-
tions [39].
A limitation of this study is the relative small sample size of the
three groups, although including the largest available series
describing nutritional status and intestinal absorption of RCDII and
EATL patients. Besides, we realize that the deﬁned fecal carbohy-
drate content (calculated from the ‘remaining fecal energy’, thus
not explained energy fraction of the stools) was partly inaccurate,
since it included indigestible ﬁbres and lactic acid due to ex-vivo
fermentation of carbohydrates. As the fecal osmolality had not
been measured we could not (semi-)quantify how much these
indigestible ﬁbres contributed to the overall assessment.
In conclusion, the nutritional status of RCDII and EATL patients
at presentation was seriously disturbed, much more than that of
newly diagnosed naive CD patients. Both fecal losses as well as
energy expenditure were much higher than expected (described as
the phenomenon of hypermetabolism) contributing to (severe)
malnutrition at diagnosis. RCDII patients more often had a chronic
form of malnutrition, presenting with a low BMI (<18.5 kg/m2),
while EATL patients presented more often with acute malnutrition
(substantial weight loss with a BMI >18.5 kg/m2 and <25 kg/m2). In
addition, this study may underline the clinical importance of using
comprehensive measures of nutritional status and energy balance,
speciﬁcally in RCDII and EATL patients. The (suspicion of a) diag-
nosis of RCDII or EATL should therefore initiate an extensive diag-
nostic nutritional assessment as an incorporated part of the
diagnostic work up, medical treatment, and follow-up of these
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